Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

NCT04116918 is registered in ClinicalTrials.gov with Baodong Qin as lead sponsor.

NCT NCT04116918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04116918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Lead sponsor
Baodong Qin
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2019
Completion date
September 30, 2021
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, egfr t790m-negative, js001, nsclc stage iv